What is the recommended dose of BPC-157?

- **Look for:** Nothing. BPC-157 is not an approved drug and there is no pharmaceutical-grade, validated formulation of it anywhere in the world (Mateescu 2026). There is no quality mark that makes...

Is BPC-157 safe to take daily?

BPC-157 is rated "Generally Safe" based on clinical evidence. Always consult your healthcare provider before starting any supplement.

LOADINGLoading your Pro surface...

Ingredient Research

Graded against 173,636 supplements + 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, NIH DSLD

BPC-157

MODERATE EVIDENCEAmino AcidLast updated April 2026

AVELOR SUMMARY

No human trials. BPC-157 is a synthetic 15 amino acid peptide (GEPPPGKPADDAGLV) with three decades of rodent data and essentially no human evidence: a 2026 narrative review searching PubMed, Embase, Cochrane, patent databases and regulatory agency sites through April 2026 found no approved formulation, no validated dosing regimen, no completed Phase II trial, and total published human exposure of fewer than 30 subjects across three uncontrolled pilot studies (Mateescu 2026, PMID: 42198317). A 2025 scoping review reached the same count of three human pilot studies and zero randomized controlled trials (McGuire 2025, PMID: 40789979). The animal work is real and reasonably consistent, showing faster tendon, muscle and gastrointestinal healing in rats at microgram-per-kilogram intraperitoneal doses, but no rodent healing result has ever been reproduced in a controlled human trial, and the only formal pharmacokinetic study was done in rats and beagle dogs, not people (He 2022, PMID: 36588717). BPC-157 has not been approved by the FDA or other global regulatory authorities, and it was temporarily added to the World Anti-Doping Agency prohibited list in 2022, though that same review notes it is not currently listed as banned by WADA (Józwiak 2025, PMID: 40005999). A separate 2026 review reached the same conclusion, that human research remains limited to small pilot studies in musculoskeletal pain, interstitial cystitis and intravenous administration (Yuan 2026, PMID: 41898733). Avelor does not score BPC-157 as a dietary ingredient. If you find it on a product label or in an injectable vial sold online, treat that as a regulatory red flag rather than as evidence of benefit. The honest summary is that the human safety profile is uncharacterized: "no adverse events reported" across fewer than 30 uncontrolled subjects is not a safety database, it is an absence of one.

WHAT IT DOES

Everything in this section is preclinical. It describes what rodent and cell-culture studies report, not a validated mechanism in humans.

BPC-157 is a synthetic partial sequence of a protein fragment identified in gastric juice, and it is unusually stable in gastric acid for a peptide of its size. In rat models the dominant reported mechanism is modulation of angiogenesis: immunohistochemical analysis of crushed muscle and transected muscle and tendon showed upregulated VEGF expression and increased CD34 and Factor VIII vessel markers in treated animals, while the peptide had no direct angiogenic effect on cells in culture, suggesting the effect is indirect and depends on an injured tissue environment (Brcic 2009, PMID: 20388964). Reviews of the musculoskeletal literature describe convergence on VEGFR2 and nitric oxide synthesis through the Akt-eNOS axis, along with ERK1/2 signaling (McGuire 2025, PMID: 40789979).

At the cell level, BPC 157 accelerated outgrowth of tendon fibroblasts from rat Achilles tendon explants and dose-dependently increased fibroblast migration and spreading through increased phosphorylation of FAK and paxillin, without directly increasing proliferation (Chang 2011, PMID: 21030672). A separate cell study found growth hormone receptor to be among the most strongly upregulated genes in BPC 157-treated rat tendon fibroblasts, which increased proliferation when growth hormone was added (Chang 2014, PMID: 25415472).

The unresolved problem is translational, not mechanistic. Plasma half-life of the intact peptide is under 30 minutes in two animal species and in a preliminary two-subject human pilot, yet reported biological effects persist for hours to days, and that disconnect remains unexplained (Mateescu 2026, PMID: 42198317). Until human pharmacokinetics and a controlled trial exist, mechanism remains a hypothesis, not evidence of benefit.

OPTIMAL DOSAGE

Look for: Nothing. BPC-157 is not an approved drug and there is no pharmaceutical-grade, validated formulation of it anywhere in the world (Mateescu 2026). There is no quality mark that makes an unapproved investigational peptide a reasonable purchase.
Red flags, all of which are common: vials labeled "research chemical" or "not for human consumption"; reconstitution instructions supplied by the seller rather than a pharmacist; certificates of analysis hosted by the seller with no independent lab named; stacking with other unapproved peptides such as TB-500; claims of tendon, gut or injury benefit citing rat studies as if they were human trials.
Sterility and content risk: injectable products purchased online are not manufactured under enforceable pharmaceutical standards. Actual peptide content, purity, endotoxin load and sterility are unverified, and an injection carries infection risk that an oral supplement does not.
Regulatory reality: BPC-157 has not been approved for use in standard medicine by the FDA or other global regulatory authorities, and its wide availability comes through non-regulated sources (Józwiak 2025, McGuire 2025).
Athletes: BPC-157 was temporarily added to the WADA prohibited list in 2022 and, per that same 2025 review, is not currently listed as banned (Józwiak 2025). Prohibited lists are revised annually. Check the current WADA list yourself before any use, and assume that an unregulated vial may contain substances that are not on its label.
These statements have not been evaluated by the Food and Drug Administration. This content is informational and is not medical advice.

Scan a supplement containing BPC-157

SAFETY PROFILE

No human drug interaction study of BPC-157 has ever been conducted. Every row below is inferred from animal data or from the absence of data. None of it should be read as a characterized interaction profile.

Critical Interactions (Do Not Combine Without Medical Supervision)

Moderate Interactions (Monitor Closely)

Theoretical/Low-Risk Interactions

WHO SHOULD BE CAREFUL

RELATED RESEARCH

5-HTP5-HTP (5-hydroxytryptophan) is an amino acid naturally produced in the body from

Acetyl-L-CarnitineMeta-analysis of 21 double-blind RCTs found significant cognitive improvement in MCI and early Alzhe

L-ArginineMeta-analysis of 11 RCTs: arginine reduced systolic BP by 5.39 mmHg and diastolic by 2.66 mmHg at do

BCAAs / EAAs

Scan Your BPC-157 Supplement Browse all ingredients

Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated: April 2026

Not medical advice. Based on published clinical research and systematic reviews.

Discover More

Explore

Browse All 834 Ingredients Browse All 20 Conditions